(Total Views: 606)
Posted On: 08/02/2019 10:32:45 PM
Post# of 72446
My guess is they want to finish developing the oral formulation work for Kevetrin in Ovarian Cancer and ready it for a phase 2 and a partnership/license by no later than early-mid Spring 2020.
Hence, raising capital to get an expert formulator to finish the oral Kevetrin formulation work.
Maybe similar to the B-IBD plans where they announced in Jan 2019 of an oral UC trial to start late 2019. After viewing proposal requests for IBD formulation, on June 6 2019 they chose BDD Pharma to develop the oral formulation for the UC trial ready late 2019. Shortly therafter, July 22, a license deal was struck for UP and funds for a UC trial.
IMO negotation talks for Kevetrin are about who will do the oral K formulation, all guided thru the advice from the potential partners.
Some may say Oral K is almost done, but maybe the potential partner wants someone chosen who is highly successful in this type of oral formulation work.
Other than a BOM license, that seems to be the primary K goal.
Hence, raising capital to get an expert formulator to finish the oral Kevetrin formulation work.
Maybe similar to the B-IBD plans where they announced in Jan 2019 of an oral UC trial to start late 2019. After viewing proposal requests for IBD formulation, on June 6 2019 they chose BDD Pharma to develop the oral formulation for the UC trial ready late 2019. Shortly therafter, July 22, a license deal was struck for UP and funds for a UC trial.
IMO negotation talks for Kevetrin are about who will do the oral K formulation, all guided thru the advice from the potential partners.
Some may say Oral K is almost done, but maybe the potential partner wants someone chosen who is highly successful in this type of oral formulation work.
Other than a BOM license, that seems to be the primary K goal.
(0)
(0)
